(December 8, 2010 – PRNewswire) — Audax Medical Inc., a privately held medical device company specializing in the development of osteobiologics, has entered into a comprehensive license agreement with Brown University, acquiring exclusive rights to a proprietary osteobiologic nanotechnology. The biomaterial, Arxis, is being developed for use in multiple clinical applications for the regeneration of diseased bone, cartilage, and other soft tissues.
|
|
|
Figure. Twin-based linker molecules, top left, self-assemble into six-molecule rings. Stacked in a tube shape, the rings of molecules not only provide a new scaffold for bone growth, but can also store growth factors and helpful drugs inside. Credit: Websterlab/Brown University |
An additional research agreement has been completed with the Brown University School of Engineering and Department of Orthopedics to further support clinical development of the technology. The technology will be used to expand Audax Medical’s regenerative osteobiologics and soft tissue platforms.
Under the terms of the agreement, Audax Medical has obtained exclusive license to a platform of intellectual property and technologies co-developed by Thomas Webster, Brown professor of engineering, addressing the treatment of degenerative bone and soft tissues.
The Arxis biomaterial consists of organic nanomolecules that have the potential to meet an array of clinical needs. The implantable material can incorporate varying growth agents that allow its end characteristics to be customized for multiple clinical and regenerative indications throughout the musculoskeletal system.
More information about the science behind the technology, including pictures and video, can be found at http://today.brown.edu/articles/2010/11/audax.
Audax Medical Inc. is a privately held medical device company developing treatment of degenerative bone and musculoskeletal tissue by promoting the growth of natural bone and tissue. For more information visit, www.audaxmed.com
Follow Small Times on Twitter.com by clicking www.twitter.com/smalltimes. Or join our Facebook group